EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Belgian observational survival data (incidence years 2004–2017) and expenditure for innovative oncology drugs in twelve cancer indications

Mattias Neyt, Carl Devos, Nancy Thiry, Geert Silversmit, Cindy De Gendt, Nancy Van Damme, Diego Castanares-Zapatero, Frank Hulstaert, Leen Verleye

European Journal of Cancer · 2023

DOI: 10.1016/j.ejca.2022.12.029 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift European Journal of Cancer, 2023. Verfasst von Mattias Neyt und 8 weiteren Autor:innen. Beteiligte Einrichtung: Belgian Health Care Knowledge Centre (KCE), Belgium. Electronic address: Mattias.Neyt@kce.fgov.be. Hauptthemen laut MEDLINE: Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Belgian Health Care Knowledge Centre.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The Food and Drug Administration and European Medicines Agency typically approve market access for cancer drugs based on surrogate end-points, which do not always translate into substantiated improvements in outcomes that matter the most to patients, i.e. survival and quality of life. These drugs often, also, have a high price tag. We assessed whether there was an increase in cancer drug expenditure for a broad selection of indications, and whether this correlates with increased overall survival. METHODS: This cohort study used Belgian Cancer Registry data from 125,692 patients (12 cancer indications, incidence period 2004-2017), which was linked to reimbursement and survival data. This reliably represents the Belgian situation. One-to-five year observed survival probability, median survival time, oncology drug expenditure and mean oncology drug cost per patient were reviewed. FINDINGS: In almost all indications, total expenditure and average treatment cost for oncology drugs increased over the years (2004-2017). In contrast, mixed findings are observed for the evolution in overall survival probability and median survival time. While an absolute improvement in the 3-year survival probability of about 10% is noticed in non-small-cell lung cancer and chronic myeloid leukaemia, improvements in about half of the other indications are limited or even absent. INTERPRETATION: The Belgian observational data indicate that assuming 'innovative' oncology drugs always add value in terms of improved survival is often unjustified. The literature also highlights the problem of using surrogate end-points, and the lack of comparative evidence showing an added value of oncology drugs for both survival and quality of life at market approval or during the post-marketing phase. Comparative studies should be conducted in the pre-marketing phase that are suitable for registration purposes, aid reimbursement decisions and support physicians and patients when making treatment decisions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsCarcinoma, Non-Small-Cell LungLung NeoplasmsNeoplasmsHumansBelgiumCohort StudiesDrug ApprovalHealth ExpendituresIncidenceQuality of Life

Stichwörter der Autor:innen

Antineoplastic agentsHigh-costInvestigationalObservational studyTechnologyTherapies

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Belgian Health Care Knowledge Centre (KCE), Belgium. Electronic address: Mattias.Neyt@kce.fgov.be.
  • Belgian Health Care Knowledge Centre (KCE), Belgium.
  • Belgian Cancer Registry (BCR), Belgium.

Förderung

  • Belgian Health Care Knowledge Centre

Zitieren

APA

Neyt, M., Devos, C., Thiry, N., Silversmit, G., De Gendt, C., Van Damme, N., Castanares-Zapatero, D., Hulstaert, F., & Verleye, L. (2023). Belgian observational survival data (incidence years 2004–2017) and expenditure for innovative oncology drugs in twelve cancer indications. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2022.12.029

Vancouver

Neyt M, Devos C, Thiry N, Silversmit G, De Gendt C, Van Damme N, et al. Belgian observational survival data (incidence years 2004–2017) and expenditure for innovative oncology drugs in twelve cancer indications. European Journal of Cancer. 2023. doi:10.1016/j.ejca.2022.12.029

BibTeX
@article{Neyt2023,
  author = {Neyt, Mattias and Devos, Carl and Thiry, Nancy and Silversmit, Geert and De Gendt, Cindy and Van Damme, Nancy and Castanares-Zapatero, Diego and Hulstaert, Frank and Verleye, Leen},
  title = {Belgian observational survival data (incidence years 2004–2017) and expenditure for innovative oncology drugs in twelve cancer indications},
  journal = {European Journal of Cancer},
  year = {2023},
  doi = {10.1016/j.ejca.2022.12.029}
}
Kostenlos starten →